CELU Financials: Celularity Inc AI Analysis



Financials

CELU Financial

Celularity Inc

$1.23

-0.8%

$-0.01

At close: Apr 17, 16:00:00 GMT-4

$1.28

4.06%

$0.05

Post-market: Apr 17, 20:00:00 GMT-4

Overview Forecast Earnings Dividends Financials

Key Stats

Prev.Close

$1.24

Open

$1.24

Day's Range

$1.23 - $1.28

52 week range

$1.01 - $4.35

Volume

25.7K

Avg.Volume

159.8K

Dividend yield

EPS (TTM)

-3.33

Market Cap

$36.9M

What is CELU?

Celularity, Inc. is a clinical stage biotechnology company, which engages in the development of off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer and immune and infectious diseases. The company is headquartered in Florham Park, New Jersey and currently employs 123 full-time employees. The company went IPO on 2019-05-23. The firm is developing and commercializing advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies, all derived from the postpartum placenta. Its therapeutic programs target aging-related diseases, including degenerative diseases, cancer, and immune disorders, using mesenchymal-like adherent stromal cells, T-cells engineered with CAR (CAR T-cells), and genetically modified and unmodified natural killer (NK) cells. The company develops, manufactures and commercializes advanced biomaterial products derived from structural tissue components of the postpartum placental tissues, including the umbilical cord. Its advanced biomaterials include Celularity Tendon Wrap, FUSE Bone Void Filler and Celularity Placental Matrix. Its advanced biomaterial products include Biovance, Biovance 3L, CentaFlex, Interfyl and Rebound products.

Features

Resources

Market

Income

Balance sheet

Cash flow

Annual

Quarterly

CELU Income

Financials in millions USD. Fiscal year is February - January.

Breakdown	TTM	09/30/2025	06/30/2025	03/31/2025	12/31/2024	09/30/2024
Revenue	40	5	5	11	18	9
Revenue Growth (YoY)	-17%	-44%	-57.99%	-21%	50%	200%
Cost of Revenue	20	3	5	3	7	3
Gross Profit	20	1	0	7	10	5
Selling, General & Admin	52	9	12	14	16	13
Research & Development	15	4	3	3	3	3
Operating Expenses	69	14	16	18	20	17
Other Non Operating Income (Expenses)	-16	-5	-6	-1	-2	-2
Pretax Income	-80	-23	-24	-19	-13	-16
Income Tax Expense	0	0	--	--	0	0
Net Income	-80	-23	-24	-19	-13	-16
Net Income Growth	135%	44%	300%	-14%	-244%	-83%
Shares Outstanding (Diluted)	26.34	26.34	24.02	23.53	22.29	22
Shares Change (YoY)	20%	20%	9%	12%	24%	17%
EPS (Diluted)	-3.06	-0.87	-1.02	-0.84	-0.59	-0.73
EPS Growth	94%	20%	240%	-18%	-210%	-85%
Free Cash Flow	-6	-4	0	-2	0	0
Free Cash Flow Per Share	--	--	--	--	--	--
Gross Margin	50%	20%	0%	63.63%	55.55%	55.55%
Operating Margin	-120%	-240%	-300%	-90.9%	-50%	-133.33%
Profit Margin	-200%	-459.99%	-480%	-172.72%	-72.22%	-177.77%
Free Cash Flow Margin	-15%	-80%	0%	-18.18%	0%	0%
EBITDA	-41	-11	-14	-9	-8	-11
EBITDA Margin	-102.49%	-220%	-280%	-81.81%	-44.44%	-122.22%
D&A For EBITDA	7	1	1	1	1	1
EBIT	-48	-12	-15	-10	-9	-12
EBIT Margin	-120%	-240%	-300%	-90.9%	-50%	-133.33%
Effective Tax Rate	0%	0%	--	--	0%	0%

Follow-Up Questions

What are Celularity Inc's key financial statements?



According to the latest financial statement (Form-10K), Celularity Inc has a total asset of $0, Net loss of $0

What are the key financial ratios for CELU?



Celularity Inc's Current ratio is 0, has a Net margin is 0, sales per share of $0.

How is Celularity Inc's revenue broken down by segment or geography?



Celularity Inc largest revenue segment is Degenerative Disease, at a revenue of 48,392,000 in the most earnings release.For geography, United States is the primary market for Celularity Inc, at a revenue of 54,220,000.

Is Celularity Inc profitable?



no, according to the latest financial statements, Celularity Inc has a net loss of $0

Does Celularity Inc have any liabilities?



no, Celularity Inc has liability of 0

How many outstanding shares for Celularity Inc?



Celularity Inc has a total outstanding shares of 0

Celularity Inc (CELU) Financial

CELU Stock Price Chart